You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Medtronic
Mallinckrodt
AstraZeneca
Merck

Last Updated: March 31, 2020

DrugPatentWatch Database Preview

ADMELOG Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Admelog patents expire, and what generic alternatives are available?

Admelog is a drug marketed by Sanofi-aventis Us and is included in one NDA. There are nineteen patents protecting this drug.

The generic ingredient in ADMELOG is insulin lispro. There are forty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the insulin lispro profile page.

US ANDA Litigation and Generic Entry Outlook for Admelog

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for ADMELOG
Drug Prices for ADMELOG

See drug prices for ADMELOG

Pharmacology for ADMELOG
Ingredient-typeInsulin
Drug ClassInsulin Analog
Synonyms for ADMELOG
GFX7QIS1II
Insulin lispro [USAN:USP:INN:BAN]
Liprolog
Lispro
LY 275585
UNII-GFX7QIS1II

US Patents and Regulatory Information for ADMELOG

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196-003 Oct 19, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi-aventis Us ADMELOG SOLOSTAR insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196-002 Dec 11, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sanofi-aventis Us ADMELOG SOLOSTAR insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196-002 Dec 11, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ADMELOG

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2498802 300883 Netherlands   Start Trial PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REGISTRATION NO/DATE: EU/1/16/1157 20170113
0368187 SPC/GB00/022 United Kingdom   Start Trial PRODUCT NAME: INSULIN GLARGINE (LANTUS) OPTIONALLY IN THE FORM OF ESTERS THEREOF OR PHYSIOLOGICALLY TOLERATED SALTS THEREOF.; REGISTERED: UK EU/1/00/134/001 20000609; UK EU/1/00/134/002 20000609; UK EU/1/00/134/003 20000609; UK EU/1/00/134/004 20000609; UK EU/1/00/134/005 20000609; UK EU/1/00/134/006 20000609; UK EU/1/00/134/007 20000609
2107069 35/2013 Austria   Start Trial PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC AND INSULIN ASPART UND BELIEBIGE ZN2+-KOMPLEXE DAVON; REGISTRATION NO/DATE: EU/1/12/806/001, EU/1/12/806/004, EU/1/12/806/005, EU/1/12/806/007, EU/1/12/806/008 (MITTEILUNG) 20180123
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Medtronic
Mallinckrodt
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.